STTK Dec 2024 12.500 call
| Previous close | 3.7300 |
| Open | N/A |
| Bid | 0.9000 |
| Ask | 1.8000 |
| Strike | 12.50 |
| Expiry date | 2024-12-20 |
| Day's range | 3.7300 - 3.7300 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
ZacksShattuck (STTK) Announces Positive Interim Data on Cancer Drug
Shattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute myeloid leukemia indications for lead candidate SL-172154, following encouraging interim data from the phase IB dose expansion study.
GlobeNewswireShattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had not yet been reached – – Observed 43% ORR in frontline TP53m AML patients, 33% CR/complete remission with incomplete hematologic recovery (CRi) and median overall survival had not yet been reached – – SL-172154 demonstrated a manageable interim safety profile in combination with AZA –
- GlobeNewswire
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that the U.S. FDA has granted orphan drug designation (ODD) to lead clinical candidate SL-172154 for the treatment of AML. “AML patients have few options for treatment and a po
